Alkermes plc

Alkermes plc

42.11
EUR
-0.52
(-1.22%)
6.00BMarket Cap
Feb 17Next Earn
Alkermes plc
MUN:8AK
(Munich Stock Exchange)

Recent

price

42.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
1.88
1.95
3.4
4.37
4.26
4.21
4.92
5.89
7.05
7.46
6.54
7.29
6.79
10.01
9.42
8.96
- -
Revenue per Share
-0.42
-0.48
-0.99
0.19
-0.21
-1.52
-1.38
-1.03
-0.9
-1.25
-0.7
-0.3
-0.97
2.14
2.22
1.47
- -
Basic EPS, GAAP
-0.3
-0.16
-4.48
0.79
-0.15
-0.62
-0.71
-0.21
0.19
-0.12
0.26
0.45
-0.11
2.13
2.45
2.92
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.33
4.08
6.54
7.12
9.47
8.72
7.93
7.81
7.52
6.88
6.7
6.87
6.35
7.2
9.03
10.99
11.1
Book Value per Share
4.33
4.08
1.1
2.12
5.58
5.59
5.24
5.54
5.7
5.34
5.42
5.84
5.62
6.69
8.52
10.48
-2.79
Tangible Book Value per Share
95
96
115
132
145
149
151
153
155
157
159
161
164
166
165
165
167
Basic Weighted Avg Shares
178
187
390
576
619
628
746
903
1,094
1,171
1,039
1,174
1,112
1,663
1,558
1,476
- -
Sales/Revenue/Turnover
-24.14
-24.45
-10.89
16.93
-14.08
-35.7
-27.98
-16.37
-9.06
-13.84
-10.82
8.33
-0.55
24.9
27
17.21
- -
Operating Margin (%)
25
9
48
74
98
86
94
99
104
80
82
79
78
75
29
27
- -
Depreciation Expense
-40
-46
-114
25
-30
-227
-208
-158
-139
-197
-111
-48
-158
356
367
242
- -
Net Income, GAAP
- -
- -
- -
29.51
- -
- -
- -
- -
- -
- -
- -
12.91
- -
- -
16.14
17.08
- -
Effective Tax Rate (%)
-22.23
-24.4
-29.15
4.34
-4.86
-36.15
-27.95
-17.48
-12.73
-16.79
-10.67
-4.1
-14.24
21.39
23.57
16.37
- -
Profit Margin (%)
247
205
250
323
746
519
579
518
643
571
673
591
633
965
950
1,386
929
Working Capital
- -
- -
441
362
349
284
281
278
276
280
392
397
367
363
69
63
1,537
LT Debt
413
392
854
952
1,397
1,314
1,209
1,203
1,171
1,085
1,067
1,113
1,044
1,203
1,465
1,819
1,865
Total Equity
- -
- -
- -
4.4
- -
- -
- -
- -
- -
- -
- -
5.66
- -
- -
22.65
12.28
- -
Return on Invested Capital (%)
- -
- -
- -
4.54
- -
- -
- -
- -
- -
- -
- -
-2.55
- -
- -
24.78
14.69
- -
Return on Capital (%)
-9.35
-11.32
-18.25
2.77
-2.56
-16.76
-16.52
-13.1
-11.74
-17.43
-10.3
-4.42
-14.68
31.67
27.52
14.72
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
34
- -
34
LT Borrowings
1,484
- -
1,471
LT Finance Leases
64
- -
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
166
168
168
Market Capitalization
5,080
8,824
6,803

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,359
- -
1,581
Cash, Cash Equivalents & STI
512
- -
755
Accounts Receivable, Net
408
- -
459
Inventories
337
- -
261
Total Current Liabilities
599
- -
652
Payables & Accruals
512
- -
531
ST Debt
34
- -
34
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.91%
11.86%
24.19%
Free Cash Flow
-289.07%
-432.86%
18.41%
Net Income, GAAP
-23.05%
-36.75%
-34.16%
Sales/Revenue/Turnover
10.24%
9.14%
-5.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
350
399
378
430
1,558
2025
307
391
394
385
1,476
2026
393
- -
480
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.54
0.57
0.9
2.22
2025
0.14
0.53
0.5
0.3
1.47
2026
-0.4
- -
0.1
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Alkermes plc (Nasdaq: ALKS) develops, manufactures and commercializes treatments for central nervous system (CNS) disorders, addiction and oncology. The company offers proprietary products including Vivitrol (extended-release naltrexone injection) for alcohol and opioid use disorders; Aristada and Aristada Initio (aripiprazole lauroxil) for schizophrenia; Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder; and Alkermes' oncology portfolio featuring Nemvaleukin alfa, a novel interleukin-2 variant cytokine in clinical development for advanced solid tumors. Alkermes provides contract development and manufacturing services through its Alkermes Pharma subsidiary, specializing in drug formulation, aseptic fill-finish and particle engineering for complex injectable and inhaled therapeutics. Founded in 1987 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States and Ireland, with commercial activities focused on specialty pharmaceuticals for healthcare providers, payers and patients in neurology, addiction and cancer treatment markets. In 2024, Alkermes advanced its oncology pipeline by initiating a Phase 3 clinical trial for nemvaleukin alfa in melanoma following positive Phase 2 data; completed a strategic licensing agreement with Janssen Biotech for a novel CD38-targeting antibody-drug conjugate; and reported a $200 million milestone payment from a prior collaboration while optimizing its neuroscience portfolio through cost-saving measures amid patent expirations.

Company News

  • Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

  • Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

  • Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript

  • What Alkermes (ALKS) Said on Its Q3 Earnings Call

  • Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

  • Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

  • Alkermes plc Reports Third Quarter 2026 Financial Results

  • Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast

  • Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

  • Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story

  • Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.

  • Alkermes to Report Third Quarter Financial Results on November 3, 2026

  • Alkermes to Report Third Quarter Financial Results on November 3, 2026

  • Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

  • Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue

  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

  • 4 CNS Drug Stocks Worth Watching This World Mental Health Day

  • Stock Picks From Seeking Alpha's September 2026 New Analysts

  • Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)

  • LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?